Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

No cookies to display.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

No cookies to display.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

No cookies to display.


Home > Cardiology > AHA 2020 > CVD Risk Reduction > Remote risk management programme effective and efficient

Remote risk management programme effective and efficient

Presented by
Prof. Benjamin Scirica, Brigham and Women’s Hospital, USA
Conference
AHA 2020
    A remote, algorithm-based programme to manage uncontrolled low-density lipoprotein (LDL) cholesterol and/or blood pressure is an effective and efficient way to optimise guideline-directed therapy across large populations, without the need for in-person visits [1].

    The study results were presented by Prof. Benjamin Scirica (Brigham and Women's Hospital, USA) and simultaneously published in Circulation [1,2]. Prof. Scirica explained that undertreatment of hypercholesterolaemia and hypertension remains a problem. Thus, a remotely delivered, algorithmically-driven disease management programme was designed and implemented. In this programme, navigators and pharmacists, supported by specialists, initiated and titrated medications. Between January 2018 and May 2020, a total of 5,000 patients were enrolled in the cholesterol and hypertension programmes. During the COVID-19 pandemic, enrolment increased by nearly a quarter.

    Among the 3,939 patients included in the cholesterol programme, 1,385 (35%) had established atherosclerotic cardiovascular disease (ASCVD); 995 (25%) had diabetes but no ASCVD; 1,247 (32%) had LDL cholesterol >190 mg/dL. In the group as a whole, an LDL cholesterol reduction of 24 mg/dl (18%) was achieved; in those who completed titration, it was 52 mg/dl (42%) (each P<0.001). The use of lipid-lowering therapy increased significantly.

    The 1,437 patients in the hypertension programme achieved an average systolic and diastolic blood pressure reduction of 14 mmHg and 6 mmHg, respectively (each P<0.001). The percentage of patients on 1, 2, 3, or 4 antihypertensive medications changed from 42%, 25%, 7%, and 2% at baseline to 31%, 35%, 19%, and 5%, respectively, during maintenance (P<0.001). There were no serious adverse programme-related outcomes.

    Prof. Scirica concluded that their programme provides a model for expanding remote healthcare delivery that may help to increase access to care, reduce health inequities, and improve healthcare quality.

     


      1. Scirica BM, et al. GLP1 RAs: The Clinical Trial Data. LBS.09, AHA Scientific Sessions 2020, 13–17 Nov.
      2. Scirica BM, et al. Circulation. 2020;142:00–00. Doi:10.1161/CIRCULATIONAHA.120.051913.

     



    Posted on